Company intelligence / Profile preview
InfectoPharm
- Ownership
- Private
- Employees
- ~450
- Development stage
- Commercial
Overview
InfectoPharm has a commercial-stage portfolio with over 140 products marketed in more than thirty countries. The company leads the German pediatric pharmaceutical market and has expanded into dermatology and hospital antibiotics. It regularly introduces new formulations to address unmet needs in pediatrics and infectious disease management. Notable recent launches include unique oral solutions for croup treatment and innovative topical therapies for skin conditions.
- Therapeutic areas
- PulmonologyImmunologyDermatologyOtherInfectious Diseases
- Modalities
- Small moleculeProtein/peptide-based drugsMedical device therapiesOTC productsCosmetics
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on InfectoPharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InfectoPharm.